Pheochromocytoma
Therapeutic area
Oncology
Rare disease
No
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pheochromocytoma
- Therapeutic area
- Oncology
- pheochromocytoma
- phaeochromocytoma
- All therapeutic areas
- Oncology
Sources for recorded values
- Severity
- Moderate
- MONDO ID
- MONDO:0008233
- Parent condition
- MONDO:0005165
Related records
Broader conditions (7)
- Benign neoplasm
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (2)
- MAX-related tumor predisposition
- TMEM127-related tumor predisposition
Trials (160)
- "Receptor Radionuclide Therapy With 177Lu-DOTATOC
- [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
- 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
- 131MIBG to Treat Malignant Pheochromocytoma
- 18F-FDOPA PET in Neuroendocrine Tumours
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
- 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
- 18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
- 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
- 211At-MABG in Adults With Advanced Neuroendocrine Cancers
- A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
- A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
- A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
- A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
- A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
- A Prospective Cohort Study for Patients With Adrenal Diseases
Approved drugs (4)
- Iobenguane I 123
- Iobenguane I 131
- Iobenguane sulfate I 131
- Metyrosine
Drugs in development (29)
- Atezolizumab Phase 2
- Avelumab Phase 1
- Belzutifan Phase 2
- Benmelstobart Phase 2
- Cabozantinib Phase 2
- Catequentinib Phase 2
- Catequentinib hydrochloride Phase 2
- Cisplatin Phase 2
- Dovitinib Phase 2
- Everolimus Phase 2
- Fostamatinib disodium Phase 2
- Gemcitabine Phase 2
- Guadecitabine Phase 2
- Guadecitabine sodium Phase 2
- Ivonescimab Phase 2
- Lenvatinib Phase 2
- Lutetium oxodotreotide Phase 2
- Lutetium oxodotreotide LU-177 Phase 2
- Nivolumab Phase 1
- Olaparib Phase 2
Other linked drugs (9)
- Dexmedetomidine
- Filgrastim
- Florbenguane F18
- Iobenguane
- Lenograstim
- Magnesium
- Pegfilgrastim
- Potassium iodide
- Vorinostat